^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tagrisso (osimertinib)

    i
    Other names: AZD9291, AZD-9291, AZD 9291
    Company:
    AstraZeneca
    Drug class:
    EGFR inhibitor
    Related drugs:
    1d
    Therapeutic Impact of Third-generation Tyrosine Kinase Inhibitors on Lung Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Mutations: A Case Description and Systematic Literature Review. (PubMed, Intern Med)
    The efficacy of TKIs was consistent across SQC forms (including de novo or adenocarcinoma-transformed cases) and EGFR mutation types. The findings indicate that, compared with early-generation TKIs, third-generation TKIs are effective against de novo SQCs and should be considered a plausible treatment option for transformed SQCs.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • simmitinib (SYHA1817)
    1d
    TATTON: AZD9291 in Combination With Ascending Doses of Novel Therapeutics (clinicaltrials.gov)
    P1, N=344, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    Tagrisso (osimertinib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • Orpathys (savolitinib) • simmitinib (SYHA1817)
    1d
    Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=64, Not yet recruiting, Chinese University of Hong Kong
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR positive
    |
    Tagrisso (osimertinib) • simmitinib (SYHA1817)
    1d
    Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib. (clinicaltrials.gov)
    P2, N=36, Recruiting, Guangzhou Medical University | Not yet recruiting --> Recruiting | Trial completion date: Mar 2026 --> Mar 2027
    Enrollment open • Trial completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • pemetrexed • simmitinib (SYHA1817)
    3d
    First Line and Treatment Sequencing in EGFR-Mutated Metastatic NSCLC: What is Right for Which Patient? (PubMed, Drugs)
    For classical EGFR mutations such as exon 19 deletion and exon 21 L858R mutation, combination strategies in the first-line setting, based on the results of the MARIPOSA (lazertinib and amivantamab) and FLAURA 2 (platinum-based doublet chemotherapy and osimertinib) trials, provide promising outcomes. Optimising the treatment sequence in advanced EGFR-mutated NSCLC is crucial to ensure the best survival outcomes along with the best treatment tolerance and quality of life. Predictive biomarkers are strongly needed as well as biomarker-based escalation and de-escalation clinical trials.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L858R + EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • Lazcluze (lazertinib) • simmitinib (SYHA1817)
    3d
    Study on the resistance mechanism of ANGPTL4 mediated by NF-Kb/HIF-1 α to osimertinib in non-small cell lung cancer (ChiCTR2600117670)
    P=N/A, N=8, Not yet recruiting, Guangdong Second Provincial General Hospital (Guangdong Provincial Emergency Hospital); Guangdong Second Provincial General Hospital (Guangdong Provin
    New trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • simmitinib (SYHA1817)
    3d
    Clinical Characteristics of Osimertinib-Related Cardiac Toxicity (ChiCTR2600117457)
    P=N/A, N=80, Not yet recruiting, The First Affiliated Hospital of Wenzhou Medical University; The First Affiliated Hospital of Wenzhou Medical University
    New trial
    |
    Tagrisso (osimertinib) • simmitinib (SYHA1817)
    3d
    Exploration of the Efficacy and Safety of metronomic chemotherapy with vinorelbine capsules combined with third-generation EGFR-TKI as First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutations (ChiCTR2500115674)
    P=N/A, N=66, Not yet recruiting, Beijing hospital; Beijing hospital
    New trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • Ameile (aumolertinib) • vinorelbine tartrate • Ivesa (firmonertinib) • simmitinib (SYHA1817)
    3d
    The Study on the Mechanism of Osimertinib-induced Pulmonary Toxicity through Up-regulating TRAPPC9 in Lung Epithelial Cells to Activate Secretory Autophagy and Recruit Macrophages (ChiCTR2500115251)
    P=N/A, N=100, Not yet recruiting, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
    New trial
    |
    Tagrisso (osimertinib) • simmitinib (SYHA1817)
    3d
    The resistance mechanism and genetic profile of EGFRm advanced NSCLC patients who had disease progression on 1st line Osimertinib plus chemotherapy(SURPASS study) (ChiCTR2500113266)
    P=N/A, N=100, Not yet recruiting, Shanghai Gobroad Cancer Hospital; Shanghai Gobroad Cancer Hospital
    New trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • simmitinib (SYHA1817)
    3d
    Adjuvant icotinib and osimertinib in the treatment of EGFR-mutated resectable non-small cell lung cancer: A real-world multicenter cohort study in China (ChiCTR2500112843)
    P=N/A, N=200, Not yet recruiting, Beijing Chest Hospital Capital Medical University; Beijing Chest Hospital Capital Medical University
    New trial
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53)
    |
    TP53 mutation • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Tagrisso (osimertinib) • Conmana (icotinib) • simmitinib (SYHA1817)
    3d
    Adjuvant osimertinib following SBRT in patients with unresected EGFRm stage I-II lymph node-negative (T1-3N0M0) NSCLC ： A Phase II, Prospective, Multicenter, Interventional study (SPACE) (ChiCTR2500111875)
    P=N/A, N=60, Not yet recruiting, Shandong First Medical University and Shandong Academy of Medical Sciences (Shandong Cancer Hospital ＆Institute); Shandong First Medical University
    New trial
    |
    CD4 (CD4 Molecule)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    Tagrisso (osimertinib) • simmitinib (SYHA1817)